Management of amyotrophic lateral sclerosis

Drugs

Volumn 68, Issue 8, 2008, Pages 1037-1048

  Corcia, Philippe ^a   Meininger, Vincent ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Amyotrophic lateral sclerosis, treatment; Quality of life; Riluzole, therapeutic use

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ATROPINE; BACLOFEN; BENZODIAZEPINE DERIVATIVE; BOTULINUM TOXIN A; DANTROLENE; DEXTROMETHORPHAN; DIAZEPAM; FLUVOXAMINE; FUROSEMIDE; LAXATIVE; LEVODOPA; LITHIUM; LOW MOLECULAR WEIGHT HEPARIN; MEMANTINE; METOPROLOL; MODAFINIL; NONSTEROID ANTIINFLAMMATORY AGENT; PRAMIPEXOLE; PROPRANOLOL; PYRIDOSTIGMINE; QUINIDINE; RILUZOLE; ROPINIROLE; SCOPOLAMINE; THEOPHYLLINE; TIZANIDINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYOTROPHIC LATERAL SCLEROSIS; ANXIETY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BRONCHUS SECRETION; CONSTIPATION; DECUBITUS; DEPRESSION; DYSPHAGIA; FATIGUE; GASTROESOPHAGEAL REFLUX; GASTROSTOMY; GENE MUTATION; GENETIC COUNSELING; HUMAN; HYPERSALIVATION; LUNG EMBOLISM; MOTOR DYSFUNCTION; MUSCLE CRAMP; NAUSEA; NERVE STIMULATION; NUTRITION; PAIN; PATHOLOGICAL LAUGHTER; PATIENT CARE; PHYSIOTHERAPY; QUALITY OF LIFE; RESPIRATORY FAILURE; RESTLESS LEGS SYNDROME; REVIEW; SIDE EFFECT; SLEEP DISORDER; SPASTICITY; SPEECH THERAPY; SURVIVAL TIME; VEIN THROMBOSIS; WEIGHT REDUCTION;

AMYOTROPHIC LATERAL SCLEROSIS; GENETIC COUNSELING; HUMANS; MUTATION; NUTRITIONAL SUPPORT; PHYSICAL THERAPY MODALITIES; SPEECH THERAPY; SUPEROXIDE DISMUTASE;

EID: 43749117305     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868080-00003     Document Type: Review

References (93)

1. Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med 2001; 344: 1688-700
2. Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population: validation of a scoring system and a model for survival prediction. Brain 1995; 118: 707-19
3. Andersen PM, Borasio GD, Dengler R, et al., on behalf of the EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis. Guidelines for diagnosing and clinical care of patients and relatives. Eur J Neurol 2005 Dec; 12 (12): 921-38
4. Kurland LT, Mulder DW. Epidemiologic investigations of amyotrophic lateral sclerosis: 2. Familial aggregations indicative of dominant inheritance part II. Neurology 1955; 5: 249-68
5. Mitchell JD, Borasio GD. Amyotrophic lateral sclerosis. Lancet 2007; 369: 2031-41
6. Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotrophic Lateral Scler 2000; 1: 293-9
7. Pradat PF, Bruneteau G. Clinical characteristics of ALS subsets. Rev Neurol 2006; 162: 4S29-33
8. Ringholz GM, Greene SR. The relationship between amyotrophic lateral sclerosis and frontotemporal dementia. Curr Neurol Neurosci Rep 2006; 5: 387-92
9. Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006; 314: 130-3
10. Traynor BJ, Codd MB, Corr B, et al. Amyotrophic lateral sclerosis mimic syndromes: a population based study. Arch Neurol 2000; 57: 109-13
11. Lewis RA, Sumner AJ, Brown MJ, et al. Multifocal demyelinating neuropathy with persistent conduction block. Neurology 1982; 32: 958-64
12. Isaacs JD, Dean AF, Shaw CE, et al. Amyotrophic lateral sclerosis with sensory neuropathy: part of a multisystem disorder? J Neurol Neurosurg Psychiatry 2007; 78: 750-3
13. Leigh PN, Abrahams S, Al-Chalabi A, et al. The management of motor neurone disease. J Neurol Neurosurg Psychiatry 2003 Dec; 74 Suppl. 4: iv32-47
14. La Spada A, Wilson EM, Lubahn DB, et al. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991; 352: 77-9
15. Chio A, Bottacchi E, Buffa C, et al. Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities. J Neurol Neurosurg Psychiatry 2006; 77: 948-50
16. Mizuta I, Ohta M, Ohta K, et al. Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes. Neurosci Lett 2001; 310: 117-20
17. Beltran-Parrazal L, Charles A. Riluzole inhibits spontaneous Ca2+ signaling in neuroendocrine cells by activation of K+ channels and inhibition of Na+ channels. Br J Pharmacol 2003; 140: 881-8
18. Bensimon G, Lacomblez L, Meininger V, et al. A controlled trial of riluzole in amyotrophic lateral sclerosis ALS/riluzole Study Group. N Eng J Med 1994; 330: 585-91
19. Lacomblez L, Bensimon G, Leigh PN, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996; 348: 336-7
20. Miller RG, Mitchell JD, Lyon M, et al. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2007; (1): CD001447
21. Francis K, Bach JR, DeLisa JA. Evaluation and rehabilitation of patients with adult motor neuron disease. Arch Phys Med Rehabil 1999; 80: 951-63
22. Voltz R, Borasio GD. Palliative therapy in the terminal stage of neurological disease. J Neurol 1997; 244 Suppl. 4: S2-10
23. Carter GT, Weiss MD, Lou JS, et al. Modafinil to treat fatigue in amyotrophic lateral sclerosis: an open label pilot study. Am J Hosp Palliat Care 2005; 22: 55-9
24. Miller RG, Anderson Jr FA, Bradley WG, et al. The ALS patient care database: goals, design and early results. ALS C.AR.E. Study Group. Neurology 2000; 54: 53-7
25. Kurt A, Nijboer F, Matuz T, et al. Depression and anxiety in individuals with amyotrophic lateral sclerosis: epidemiology and management. CNS Drugs 2007; 21: 279-91
26. Vojtech H, Kabrnova K, Aldhoon B, et al. Serotonin and norepinephrine reuptake inhibition and eating behavior. Ann NY Acad Sci 2006; 1083: 252-69
27. Talmi YP, Finkelstein Y, Zohar Y. Reduction on salivary flow in amyotrophic lateral sclerosis with Scopoderm TTS [letter]. Head Neck 1989; 11: 565
28. Verma A, Steele J. Botulinum toxin improves sialorrhea and quality of living in bulbar amyotrophic lateral sclerosis. Muscle Nerve 2006; 34: 235-7
29. Borasio G, Voltz R. Palliative care in amyotrophic lateral sclerosis. J Neurol 1997; 244: S11-7
30. Stalpers LJ, Moser EC. Results of radiotherapy for drooling in amyotrophic lateral sclerosis [letter]. Neurology 2002; 58: 1308
31. Cintas P. Drug therapy for symptomatic relief in ALS. Rev Neurol 2006; 162: 4S235-43
32. Newall AR, Orser R, Hunt M. The control of oral secretions in bulbar ALS/MND. J Neurol Sci 1996; 139 Suppl.: 43-4
33. Sancho J, Servera E, Diaz J, et al. Efficacy of mechanical insufflation-exsufflation in medically stable patients with amyotrophic lateral sclerosis. Chest 2004; 125: 1400-5
34. Newrick PG, Langton-Hewer R. Pain in motor neuron disease. J Neurol Neurosurg Psychiatry 1995; 48: 838-40
35. Ganzini L, Johnston WS, Hoffman WF. Correlates of suffering in amyotrophic lateral sclerosis. Neurology 1999; 52: 1434-40
36. Stefanovska A, Rebersek S, Bajd T. Effect of electrical stimulation on spasticity. Crit Rev Phys Rehabil Med 1991; 3: 59-99
37. Ukada F, Yamao S, Nagata H, et al. Pathologic laughing and crying treated with levodopa. Arch Neurol 1984; 41: 1095-6
38. Brooks BR, Thisted RA, Appel SH, et al. Treatment of pseudobulbar affect in ALS with dextrometorphan/quinidine: a randomized trial. Neurology 2004; 63: 1364-70
39. Tariq SH. Constipation in long-term care. J Am Med Dir Assoc 2007; 8: 209-18
40. Forshew DA, Bromberg MB. A survey of clinician's practice in the symptomatic treatment of ALS. Amyotroph Lateral Scler 2003; 4: 258-63
41. Bortolotti M. Laryngospasm and reflex central apnea caused by aspiration of refluxed gastric content in adults. Gut 1989; 30: 233-8
42. Oertel WH, Stiasny-Kolster K, Bergtholdt B, et al. Efficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study (effect-RLS study). Mov Disord 2007; 22: 213-9
43. Walters AS, Ondo WG, Dreykluft T, et al. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord 2004; 19: 1414-23
44. Ono S. The skin in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2000; 1: 191-9
45. Watanabe S, Yamada K, Ono S, et al. Skin changes in patients with amyotrophic lateral sclerosis: light and electro microscopic observations. J Am Acad Dermatol 1987; 17: 1006-12
46. Sasaki S, Tsutsumi Y, Tamane K, et al. Sporadic amyotrophic lateral sclerosis with extensive neurological involvement. Acta Neuropathol 1992; 84: 211-5
47. Qureshi M, Cudkowicz ME, Zhang H, et al. Increased incidence of deep venous thrombosis in ALS. Neurology 2007; 68: 76-7
48. Kimura F, Ishida S, Furutama D, et al. Wheelchair economy class syndrome in amyotrophic lateral sclerosis [letter]. Neuromuscul Disord 2006; 16: 207
49. Norris Jr FH, U KS, Sachais B, et al. Trial of baclofen in amyotrophic lateral sclerosis. Arch Neurol 1979; 36: 715-6
50. Ashworth NI, Satkunam LE, Deforge D. Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease (Review). Cochrane Database Syst Rev 2006; (1): CD004156
51. Marquandt G, Lorenz R. Intrathecal baclofen for intractable spasticity in ALS. J Neurol 1999; 256: 619-20
52. Marquandt G, Seifert V. Use of intrathecal baclofen for treatment of spasticity in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2002; 72: 275-6
53. Traynor BJ, Alexander M, Corr B, et al. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996-2000. J Neurol Neurosurg Psychiatry 2003; 74: 1258-61
54. Desnuelle C, Bruno M, Soriani MH, et al. What physical therapy techniques can be used to improve airway freedom. Rev Neurol 2006; 162: 4S244-52
55. Johnson CR. Aquatic therapy for an ALS patient. Am J Occup Ther 1988; 42: 115-20
56. Howard RS, Orrell RW. Management of motor neuron disease. Postgrad Med 2002; 78: 736-41
57. Bourke SC, Gibson GJ. Non-invasive ventilation in ALS: current practice and future role. Amyotroph Lateral Scler 2004; 5: 67-71
58. Lyall RA, Donaldson N, Polkey MI, et al. Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis. Brain 2001; 124: 2000-13
59. Radunovic A, Mitsumoto H, Leigh PN. Clinical care of patients with amyotrophic lateral sclerosis. Lancet Neurol 2007; 6: 913-25
60. Miller RG, Rosenberg JA, Gelinas DF, et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidenced-based review). Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 1999; 52: 1311-23
61. Polkey MI, Lyall RA, Green M, et al. Expiratory muscle function in amyotrophic lateral sclerosis. Am J Crit Care Med 1998; 158: 734-41
62. Polkey MI, Green M, Moxham J. Measurement of respiratory muscle strength. Thorax 1995; 50: 1131-5
63. Morgan RK, McNally S, Alexander M, et al. Use of SNIP nasal-inspiratory force to predict survival in amyotrophic lateral sclerosis. Am J Resp Crit Care Med 2005; 171: 269-74
64. Perez T. Amyotrophic lateral sclerosis (ALS): evaluation of respiratory function. Rev Neurol 2006; 162: 4S188-94
65. Pinet C. What is the role of life support systems? Rev Neurol 2006; 162: 4S266-68
66. Lechtzin N, Weiner CM, Clawson L, et al. Hospitalization in amyotrophic lateral sclerosis: causes, costs and outcomes. Neurology 2001; 56: 753-7
67. Desport JC, Preux PM, Truong TC, et al. Nutritional status is a prognostic factor for survival in ALS patients. Neurology 1999; 53: 1059-63
68. Desport JC, Torny F, Lacoste M, et al. Hypermetabolism in ALS: correlations with clinical and paraclinical parameters. Neurodegener Dis 2005; 2: 202-7
69. Dupuis L, Corcia P, Fergani A, et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology 2008; 70: 1004-9
70. Boitano LJ, Jordan T, Benditt JO. Non invasive ventilation allows gastrostomie tube placement in patients with advanced ALS. Neurology 2001; 56: 413-4
71. Gregory S, Siderowf A, Golaszewski AL, et al. Gastrostomy insertion in ALS patients with low capacity: respiratory support and survival. Neurology 2002; 58: 485-7
72. Bouteloup C. What are the means of alimentary function supply and their indications? Rev Neurol 2006; 162: 4S309-19
73. Desport JC, Mabrouk T, Bouillet P, et al. Complications and survival following radiologically and endoscopically-guided gastrostomy in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2005; 6: 88-93
74. Thornton FJ, Fotheringham T, Alexander M, et al. Amyotrophic lateral sclerosis: enteral nutrition provision-endoscopic or radiologic gastrostomy? Radiology 2002; 224: 713-7
75. Couratier P, Desport JC, Antonini MT, et al. Review of nutritional and respiratory support in ALS. Rev Neurol 2004; 160: 243-50
76. Neudert C, Olivier D, Wasner M, et al. The course of the terminal phase in patients with amyotrophic lateral sclerosis. J Neurol 2001; 248: 612-6
77. Camu W, Khoris J, Moulard B, et al. Genetics of familial ALS and consequences for diagnosis. J Neurol Sci 1999; 165: S21-6
78. Hand C, Rouleau GA. Familial amyotrophic lateral sclerosis. Muscle Nerve 2002; 25: 135-59
79. Orrell RW, Figliewicz DA. Clinical implications of the genetics of ALS and other motor neuron diseases. Neurology 2001; 57: 9-17
80. Mayeux V, Corcia P, Besson G, et al. N19S, a new superoxide dismutase gene mutation in sporadic amyotrophic lateral sclerosis: no evidence for disease causation. Ann Neurol 2003; 53: 815-8
81. Rezania K, Yan J, Dellafave L, et al. A rare Cu/Zn superoxide dismutase mutation causing familial amyotrophic lateral sclerosis with variable age of onset, incomplete penetrance and a sensory neuropathy. Amyotroph Lateral Scler 2003; 4: 162-6
82. Andersen PM, Forsgren L, Binzer M, et al. Autosomal recessive adult-onset amyotrophic lateral sclerosis associated with homozygosity for Asp90Ala Cu,Zn superoxide dismutase mutation: a clinical and genealogical study of 36 patients. Brain 1996; 119: 1153-72
83. Cudkowicz ME, McKenna-Yasek D, Sapp PE, et al. Epidemiology of mutations in SOD in ALS. Ann Neurol 1997; 41: 210-21
84. Regal L, Vanopdenbosch L, Tilkin P, et al. The G93C mutation in superoxide dismutase 1: clinicopathologic phenotype and prognosis. Arch Neurol 2006; 63: 262-7
85. Corcia P. Methods of the announcement of ALS diagnosis in familial forms. Rev Neurol 2006; 162: 4S122-6
86. Van den Berg JP, Kalmijn S, Linderman E, et al. Multidisciplinary ALS care improves quality of life in patients with ALS. Neurology 2005; 65: 1264-7
87. Nirmalananthana N, Greensmitha L. Amyotrophic lateral sclerosis: recent advances and future therapies. Curr Opin Neurol 2005; 18: 712-9
88. Cudkowicz ME, Shefner JM, Schoenfeld DA, et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol 2006; 60: 22-31
89. Gordon PH, Moore DH, Florence JM, et al. Results of the phase III randomized controlled trial of minocycline in ALS [abstract]. Neurology 2007; 68 Suppl. 1: 90
90. Gordon PH, Moore DH, Miller RG, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007; 6: 1045-53
91. Meininger V, Bensimon G, Bradley WR, et al. Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials. Amyotroph Lateral Scler 2004; 5: 107-17
92. Mazzini L, Mareschi K, Ferrero I, et al. Autologous mesenchymal stem cells: clinical applications in amyotrophic lateral sclerosis. Neurol Res 2006; 28: 523-6
93. Lepore AC, Maragakis NJ. Targeted stem cell transplantation strategies in ALS. Neurochem Int 2007; 50: 966-75